21
Participants
Start Date
March 13, 2018
Primary Completion Date
September 25, 2020
Study Completion Date
October 2, 2020
MRI
"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
New York University School of Medicine, New York
The Trustees of Columbia University in the City of New York, New York
Medical University of South Carolina, Charleston
Ohio State University, Columbus
University of Texas Southwestern Medical Center, Dallas
The Regents of the University of Colorado, Aurora
RILITE Foundation
OTHER